glp 1 medication examples How GLP-1 medications are transforming diabetes and weight loss treatment Weight loss medicine is evolving

August 2025 : The US FDA approved Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced-calorie diet and increased physical activity

The researchers also discovered the quantity of GLP-1 medication users without FDA-approved indications increased from 0.21% in 2019 to 0.37% in 2023

It is an obesity therapeutics market, an incretin therapy market, a cardiometabolic pipeline market, and an investment theme that touches nearly every major pharmaceutical growth strategy

American Journal of Medicine